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Abstract  
The aim of this review paper is to survey the literature related to DNA methylation, and its 
association with cancer and ageing. The review will outline the key factors, including diet, 
which modulate DNA methylation. Our rationale for conducting this review is that ageing and 
diseases, including cancer, are often accompanied by aberrant DNA methylation; a key 
epigenetic process, which is crucial to the regulation of gene expression. Significantly, it has 
been observed that with age and certain disease states, DNA methylation status can become 
disrupted. For instance, a broad array of cancers are associated with promoter-specific 
hypermethylation and concomitant gene silencing. This review highlights that 
hypermethylation, and gene silencing, of the EN1 gene promoter, a crucial homeobox gene,   
has been detected in various forms of cancer. This has led to this region being proposed as a 
potential biomarker for diseases such as cancer. We conclude the review by describing a 
recently developed novel electrochemical method which can be used to quantify the level of 
methylation within the EN1 promoter and emphasise the growing trend in the use of 










1.  Introduction 
The epigenetic mechanism of DNA methylation controls gene expression and repression (1). 
DNA methylation refers to the covalent addition of methyl (CH3) groups to the carbon 5 
position of the pyrimidine ring of cytosines, typically in a CpG dinucleotide, of which there 
are approximately 28 million in the haploid genome of a human (2). Regions of DNA with a 
high CpG content are referred to as CpG islands (CGIs). There are approximately 45,000 CGIs 
per human haploid genome (3), which are typically between 200 and 1400bp in length (4) and 
generally located around transcription start sites (5). Saxonov, Berg and Brutlag determined 
that 72% of promoters are rich in predominantly unmethylated CpG (5). DNA methylation 
varies due to a number of factors including, age and disease status. Interestingly, 
hypermethylation of CpG sites in promoters or enhancers typically leads to transcriptional 
silencing, whereas hypomethylation of CpG sites in a gene body frequently results in an 
increase in gene expression (6, 7).  
As outlined in Figure 1, the production of 5-methylcytosine is regulated by DNA 
methyltransferases (DNMTs) DNMT1, DNMT3A and DNMT3B, which transfer methyl 
groups from S-adenosyl-L-methionine. DNMT1 primarily acts as a maintenance 
methyltransferase, targeting hemimethylated DNA, formed after DNA replication, thus 
ensuring the re-establishment of the parental DNA methylation pattern in daughter DNA (8); 
while DNMT3A and DNMT3B act as de novo DNA methyltransferases (9). Additionally, there 
is another member of the DNMT3 family, DNMT3L. Although catalytically inactive, 
DNMT3L has been observed to markedly stimulate the de novo methylation by DNMT3A of 
DNA when coexpressed (10).  
Demethylation can be either passive, through incorrect DNA replication, or be an active 
process regulated by ten-eleven translocation (TET) enzymes. TET catalyse the oxidation of 
5-methylcytosine to 5-carboxylcytosine via the intermediates 5-hydroxymethlcytosine and 5-
formylcytosine. Thymine DNA glycosylase (TDG) then removes 5-carboxylcytosine and 5-
formylcytosine from the DNA strand allowing the insertion of an unmethylated cytosine into 




2. Impact of Ageing on DNA Methylation 
During ageing, epigenetic drift can be used to describe the increase in methylation in CGI sites 
which are unmethylated in the young, and the decrease in methylation globally. These findings 
have been reported across species (12). Maegawa et al. (2017) showed that average methylation 
increased from 2±0.1% to 18±5%, 2±0.3% to 22±3%, and 3±0.5% to 20±4 with age in sites 
observed to be unmethylated in young mice, rhesus monkeys and human subjects respectively. 
When analysing highly methylated non-CGI sites, ageing resulted in a reduction in methylation 
from 94±0.4% to 78±4%, 94±0.3% to 73±4%, and 93±1% to 74±2% in the same three 
mammalian species. These data indicate that methylation drift associated with ageing is 
evolutionarily conserved. Interestingly, drift rates were calculated as 4.1±1.2%, 0.34±0.14% 
and 0.1±0.02% per year for mice, rhesus monkeys and human respectively, and an inverse 
relationship between the rate of methylation drift and longevity in these mammalian species 
was established (12). A similar finding was described by Wilson et al. (1987). In this work, 
ageing resulted in a global decrease in 5-methyldeoxycytidine in multiple tissues from 2 murine 
models and human bronchial epithelial cells obtained from autopsy donors, and an inverse 
relationship between lifespan and rate of loss of 5-methyldeoxycytidine was reported. An 
estimated loss of 5.6-8.9 x105 and 2.3-2.8 x105 per year was observed for Mus musculus and 
Peromyscus leucopus species which have lifespans of 3.5 and 8.0 years respectively, while a 
loss of 1.6x104/year was observed in human cells (13). Their conclusion corroborates with the 
findings of Drinkwater et al. (1989), where it was determined that lymphocytes obtained from 
20-30 year old volunteer donors contained 54.6±1.6% methylated CmCGG sites, while a 
statistically significant 7.1% reduction (47.5±2.6%) was observed in 65-80 year olds (14).  
Maegawa et al. (2017) further examined if methylation drift is ubiquitous in differing tissue 
types. By analysing 12 genes which were associated with hypermethylation and 3 associated 
with hypomethylation with age, it was determined that tissue from kidney and liver generally 
exhibited lower levels of age related hypermethylation. In contrast, tissue from the intestines 
(small and large) and bone marrow showed reduced age associated hypomethylation. In further 
investigations by Maegawa et al. (2017) it was reported that there was a significant inverse 
relationship between methylation drift and the level of change in gene expression. It was noted 
that when looking at the methylation pattern of genes which had increased expression, a 
significant reduction in DNA methylation was observed, while conversely, silenced genes had 
a concomitant increase in methylation.  
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Altered expression of the enzymes responsible for DNA methylation and demethylation have 
been repeatedly reported to be a contributing factor to changes observed in DNA methylation 
patterns with age. For instance, Sun et al. (2014) observed the expression of genes encoding 
for the DNA methyltransferases dnmt1, dnmt3a, and dnmt3b, considerably declined between 
the ages of 4 months and 24 months in C57BL/6 male mice. Interestingly, the expression of 
demethylation enzymes tet1 and tet3 were also reduced with age (15). In humans, a reduction 
in TET1 and TET3 expression was observed with age and a correlation between TET1 and 
DNMT1, DNMT3B and TDG was determined in peripheral blood mononuclear cells obtained 
from 188 volunteers, aged 34-74, from eight European countries. Interestingly, while a global 
reduction in 5-hydroxymethylcytosine (5hmC) was also detected with age, a statistically 
significant increase in the methylation of the CpG islands within the TET1 gene was found in 
69-74 year olds when compared to 34-41 year olds (16). These findings are consistent with the 
observation that hypermethylation within certain gene regions is often associated with gene 
silencing.  
In contrast to the findings of Sun et al. (2014), Lopatina et al. (2001) showed that although 
dnmt1 declined with age in WI-38 fibroblast cells, the activity of de novo methylation enzymes 
decreased in middle age, compared with young cells, and rose slightly with senescence. This 
resulted in the ratio of de novo to maintenance methylation enzymes increasing with age. The 
authors postulate the decline in dnmt1 could lead to the global hypomethylation, and add that 
the rise in the ratio of de novo to maintenance methylation enzymes with age could be 
responsible for the regional hypermethylation associated with gene silencing (17). Similarly, 
Casillas Jr et al. (2003) observed that Dnmt1 expression declined significantly with age in 
foetal human WI-38 fibroblasts, with old aged cells having 75.44% of the expression exhibited 
by young cells. Furthermore, the activity of this maintenance methyltransferase declined from 
83.2cpm/μg protein in young cells to 52.1cpm/μg protein in middle aged cells, and to 
28.1cpm/μg protein in old lung WI-38 fibroblast cells. Conversely, the activity of the de novo 
methyltransferases increased from 21.4cpm/μg protein in young cells to 59.0 and 75.0cpm/μg 
protein in middle aged and old cells respectively. Interestingly, ageing appeared to have an 
opposing effect on the expression of the de novo methyltransferases, with Dnmt3a declining to 
60.61% that of young cells in old age, while expression of Dnmt3b in young cells was 75.21% 
compared to that expressed by old cells. Thus a change in the ratio between maintenance 
methyltransferases and de novo methyltransferases could be a key factor in the aberrant DNA 




3. DNA Methylation and Cancer 
Germline cells have specific DNA patterns to enable suitable gene regulation during embryonic 
development. Importantly, within a small proportion of genes, one parental allele is exclusively 
expressed, due to DNA methylation regulated gene imprinting (18). Inappropriate methylation 
during development can result in imprinting failures and diseases including Beckwith-
Wiedemann, Prader-Willi, Silver-Russell and Angelmans’s syndromes (19). Epigenetic 
modifications are also frequently seen in diseases with later onsets; including cancer (20), 
neurodegeneration (21), and autoimmune disease (22). With a focus on the effect of epigenetic 
modification on cancer pathogenesis, both gene silencing, due to hypermethylation in gene 
promoters (23), and oncogene activation or chromosomal instability due to global 
hypomethylation (24, 25) will be discussed.  
In one study of promoter hypermethylation, it was reported that in 7/9 non-small cell lung 
cancers the tumour suppressor gene p16 was fully methylated, while the CpG islands in 
samples of healthy lung, kidney, and blood lymphocytes the CpG sites were found to be 
unmethylated (23). Interestingly, Christensen et al. (2010) discovered through locus-by-locus 
analysis, a trend between loci methylation and cancer characteristics, including tumour grade 
and size, oestrogen and progesterone status and triple negative status in invasive breast cancer 
specimens, from 162 women from Northern California. Interestingly, at all 74 CpG loci which 
were associated with tumour size, there was a positive correlation between the level of 
methylation and tumour size. Moreover, increased methylation was observed in all 5 CpG loci 
associated with lymph node infiltration, when disease-positive lymph nodes were reported. 
Array validation revealed CpGs within the promoters of P2RX7, a gene encoding for a receptor 
which mediates apoptosis, and HSD17B12, a gene coding for an enzyme involved in oestrogen 
metabolism and fatty acid elongation, had statistically elevated methylation levels as tumour 
size increased, while methylation of CpGs within the promoter of GSTM2, which reduced 
mRNA expression of the detoxifying enzyme GSTM2, was correlated with tumour grade (26).  
Similarly to the aberrant DNA methylation associated with ageing, disease associated changes 
to the methylome could be due to changes in DNMT expression. For instance, in a study of 76 
women with primary cervical cancer, DNMT1 was on average observed in 77.5% of cancer 
cells, in comparison to only 16% of normal cells. In addition, the intensity score was calculated 
as 1.0 for cancerous cells compared with a reduced figure of 0.2 for normal cells. Interestingly, 
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individuals with >77.5% DNMT1 positive cells were 4.3 times more likely to die prematurely 
compared with individuals who exhibited <77.5% DNMT1 positive cells, while those with an 
intensity score >0.9625 were 4.9 times more likely to die earlier than those <0.9625 (27). 
Furthermore, Mizuno et al. (2001) determined that in 33 patients with acute myeloid leukaemia 
(AML), DNMT1, DNMT3A and DNMT3B exhibited an average 5.3, 4.4 and 11.7 fold increase 
in comparison to levels observed in control bone marrow cells (28). Interestingly, p15INA4B, a 
tumour suppressor gene commonly silenced by methylation in AML, was methylated in 72% 
of AML patients, and in these 24 cases, DNMT1 was statistically higher than those without 
p15INA4B methylation. Further examination of chronic myeloid leukaemia cells revealed that 
DNMT expression was phase dependent. During the chronic phase, expression of these three 
methyltransferases was comparable to normal bone marrow cells, however, with advancement 
to the acute phase, DNMT1, DNMT3A and DNMT3B expression was raised with an average 
3.2, 4.5 and 3.4 fold increase respectively (29). Conversely, Gaudet et al. (2003) reported that 
mice exhibiting 10% of DNMT1 compared with wild type mice, exhibited a 30% reduction in 
birth weight, and 80% developed aggressive T cell lymphoma within 8 months (24). While 
examining hypomethylated tumours, it was determined that 10/12 exhibited chromosomal 
instability (gain of chromosome 15), in comparison to only 2/12 Moloney murine leukaemia 
virus induced tumours, thus indicating that global hypomethylation can also play a role in the 
pathogenesis of cancer through chromosomal instability. 
 
3.1. EN1 Gene and Disease 
The EN1 gene encodes for the protein homeobox protein engrailed-1. First characterised in 
Drosophila, EN1 mutation results in abnormal development including posterior-anterior 
duplications and malformation of the wings (30). Within humans, the EN1 gene has been 
associated with pattern formation within the central nervous system during development (31). 
Wilson et al. (2011) detail that expression of EN1 is observed within multiple neuronal cell 
types within the cerebellum, and that significant changes to its distribution occurs during 
gestation, with expression remaining until >21 days (32). 
Hypermethylation of this gene has been observed in multiple cancer types including colorectal 
(33), prostate (34), and breast cancer (35). For instance, Bell et al. (2011) reported that the EN1 
gene transcriptional start site exhibited significant hypermethylation in human salivary gland 
adenoid cystic carcinoma when compared with normal tissue, with a 59% difference in 
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methylation across the EN1 promoter. Furthermore, the extent of hypermethylation was 
correlated with tumour grading, location and patient outcome. Significantly, it was observed 
that out of 32 loci, the EN1 gene displayed the greatest difference in methylation between 
normal and diseased tissue, and little variation in hypermethylation across 9 CpG islands, thus 
emphasising its possible use as a biomarker in cancer (36). Similarly for prostate cancer, 
differential methylation between normal and cancerous cells was greatest in the EN1 gene (34). 
In addition, the EN1 gene was most frequently methylated in colorectal cancer when compared 
to the SCTR and INHBB genes. Interestingly, EN1 was more likely to be methylated in 
colorectal carcinoma compared to colorectal adenoma, with 73% (66/90) colorectal carcinomas 
and 40% (4/10) adenomas showing hypermethylation, and result in gene silencing (33). 
Similarly, Frigola determined that the EN1 gene was hypermethylated in 70% of colorectal 
tumours, and found hypermethylation resulted in suppression of the EN1 gene (37). 
Importantly, Mayor et al. (2009) outlined that only 1.12% (1/89) of EN1 genes in normal 
samples exhibited hypermethylation, an important factor when searching for a cancer 
biomarker. Interestingly, EN1 methylation resulted in approximately a 30% reduced survival 
rate after 5 years compared to patients without hypermethylation of the EN1 gene (33).  
  
4. Effect of Poor Diet on DNA Methylation and Disease 
There is a strong association between poor diet, obesity, and cancer (38). For instance, Zhang 
et al. (2017) examined the effect of DNA methylation in rats fed a high fat diet for 14 weeks, 
and reported that within 1000bp of transcriptional start sites of known genes, 7 genes exhibited 
differentially methylated CpGs. Differential CpG methylation ranged from 5-22% difference, 
in addition to altering gene expression, in animals which gained approximately 90% body mass 
from the high fat diet in comparison to rats fed a standard chow diet. When expanding to CpGs 
within 10,000bp of transcriptional start sites, 147 genes were differentially methylated and 
expressed. One of the genes of note, Phlda1, became hypermethylated with a high fat diet, 
which was associated with reduced expression, and in turn steatosis, a contributor to the 
pathophysiology of obesity (39). Furthermore, Vucetic, Kimmel, and Reyes (2011) outlined 
that mice fed a high fat diet (60% fat) from weaning at 3 weeks, until 18-20 weeks, showed 
significant hypermethylation in the μ-opioid receptor (MOR) promoter in reward-related brain 
regions, and repression of the MOR gene, which was related to an increase in binding of the 
transcriptional repressor methyl CpG binding protein 2 (MeCP2). It was suggested that 
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repression of the MOR gene was responsible for a significantly reduced preference for sucrose; 
thus indicating that animals on a high fat diet exhibit reward hypofunctioning, which may 
contribute to difficulties reversing obesity after long term exposure to highly palatable foods 
(40). As mentioned, obesity  is strongly linked with cancer (41). For instance, it has been found 
that many of the 31 differentially methylated CpGs in obese children, and 151 differentially 
methylated CpGs in severely obese children discussed by Fradin et al. (2017) are also 
associated with cancer, thus warranting concern regarding the risk for cancer pathogenesis in 
later life (42). Similar results were observed by Xu et al. (2013), who examined differentially 
methylated CpG sites in 48 obese African American participants aged 14-20 years old 
compared to their non-obese counterparts (43). It is important to note that the type of ingested 
fat may differentially methylate DNA. Garcia-Escobar et al. (2017) examined the effect of 
different fats on TNFα promoter methylation, and reported reduced methylation in animals 
who were fed coconut oil (high SFA), which was inversely correlated with the pro-
inflammatory cytokine TNFα in adipocytes (44). 
 
5. Aberrant DNA Methylation Therapy 
There is increasing evidence suggesting the influence of lifestyle factors such as diet, physical 
activity, weight, and smoking status, on the methylome and age related disease. Due to the 
ability to somewhat modulate and reverse methylation using lifestyle factors, targeting the 
methylome more rigorously with chemotherapy could provide a promising avenue to treat 
diseases such as cancer. 
 
5.1. Diet 
The role of diet in modulating metabolic health throughout lifespan has long been known. For 
instance, a significant amount of insight has been gained from analysing the impact of being 
born during the Dutch Hunger Winter, which took place in the Netherlands during world war 
two. It is now emerging that changes to DNA methylation could be a central player in directing 
how the deleterious effects of the Dutch Hunger Winter unfold. A recent genome-scale analysis 
of differential DNA methylation in whole blood after periconceptional exposure to famine 
during the Dutch Hunger Winter emphasises this phenomenon (45). Following a thorough 
assessment of prenatal malnutrition-associated differentially methylated regions (P-DMRs), it 
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was found that P-DMRs which preferentially occur at regulatory regions, are characterized by 
intermediate levels of DNA methylation, and map to genes enriched for differential expression 
during early development. Moreover, it was revealed differential methylation of P-DMRs was 
associated with pathways which are defined by growth and metabolism. P-DMRs found in the 
insulin receptor precursor gene and the carnitine palmitoyltransferase 1A gene (involved in fat 
metabolism) were found to have enhancer activity in vitro and differential methylation was 
interconnected with birth weight and serum low density lipoprotein-cholesterol levels.  In 
addition to the findings from studying those exposed to the Dutch Hunger Winter it has also 
been recognised by Barker since the mid-1990s that exposure to a suboptimal intrauterine 
environment has deleterious metabolic consequences for later life (46).  Similar to the Dutch 
Hunger Winter, recent studies have revealed that this phenomenon is underpinned by 
epigenetic regulation. For instance, it has been shown that placental leptin gene DNA 
methylation levels were correlated with glucose levels (2-hours post-oral glucose tolerance 
test) in women with impaired glucose tolerance and with decreased leptin gene expression in 
the whole cohort (47).  The methylome is not simply a nutrient sensor during the intrauterine 
period. Strikingly, in a recent study DNA methylation changes were correlated with body 
composition in pre-school children as part of the epigenome-Wide-Analysis in the European 
Childhood Obesity Project (CHOP)-Study. It was found DNA methylation variants were 
identified to be associated with BMI, fat-mass, fat-free-mass, fat-mass-index and fat-free-
mass-index (48). Specific aspects of diet have also been associated with DNA methylation 
changes. As discussed, the effect of poor diet on aberrant DNA methylation and disease 
pathogenesis can be significant, therefore it is conceivable that a healthy diet could play a role 
in the prevention of aberrant DNA methylation. For instance, plant polyphenols, originating in 
fruit and beverages often associated with healthy diets, have been associated with reduced 
oxidative stress, inflammation and risk of cancer (49), which could be mediated through 
modulation of DNA methylation (50). In one example, polyphenols associated with the 
Mediterranean Annuraca apple, reportedly increased p53, reduced methylation in the 
promoters of hMLH1, p14ARF, and p16INK4a, restoring normal expression of silenced 
tumour suppressor genes in colorectal cancers (51). In another example, it was observed that 2 
weeks of 6g/day of cocoa, a rich source of polyphenols, led to 2.991±0.366 %5mC in 
comparison to 3.909±0.380 %5mC in peripheral leukocyte DNA from control participants with 
pre-hypertension, type 1 hypertension, or hypercholesterolaemia in a randomised controlled 
trial. Furthermore, in vitro treatment of subject peripheral blood mononuclear cells, revealed 
cocoa significantly lowered DNMT1, 3a and 3b mRNA expression in addition to 
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methylenetetrahydrofolate reductase (MTHFR) and 5-methyltetrahydrofolate-homocysteine 
methyltransferase reductase (MTRR) gene expression (52). Similar results were observed by 
Nandakumar et al. (2011) who reported that green tea polyphenols epicatechin-gallate and 
epigallocatechin-3-galate significantly lowered DNMT1, 3a and 3b activity and expression in 
a dose dependent manner, reduced global methylation, and reactivated the silenced tumour 
suppressor genes p16INK4a and Cip1/p21 in human skin cancer A431 cells (53).  
 
5.2. Folate Feeding Studies 
One of the most studied supplements in regards to DNA methylation is folate. This is because, 
folate plays a key role in one carbon metabolism through its conversion to N-5-
methyltetrahydrofolate (5-methylTHF), which in turn is converted to SAM, the global methyl 
donor in DNA methylation (54). Methyl group deprivation can lead to changes in one carbon 
folate metabolism, metabolites, which can irreversibly perturb DNA methylation and 
interestingly, induce lesions associated with the pathogenesis of cancer. For instance, Pogribny 
et al. (2006) reported that male F344 rats fed a diet deficient in methyl groups (low methionine 
and choline, and folic acid negative) for 9 weeks, exhibited a 70% reduction in SAM when 
compared to mice on a control diet, while SAH was unaffected, thus a significant decrease in 
the SAM/SAH ratio, an important predictor of methylation capacity, was observed. The 
methyl-deficient diet also led to a 60% increase in unmethylated CCGG sites obtained from 
liver tissue. Interestingly, the reintroduction of a methyl-sufficient diet resulted in normalised 
DNA methylation in rats who were fed a methyl-deficient diet for 9 weeks. However, in rats 
fed a methyl-deficient diet for 18, 24 or 36 weeks, the reintroduction of a methyl-sufficient diet 
could not reverse the hypomethylation induced. Significantly, the appearance of glutathione-
S-transferase π (GSTπ), a characteristic of hepatocarcinogenesis was observed despite the 
reintroduction of the methyl-sufficient diet, even after 9 weeks of exposure to a methyl-
deficient diet (55). Additionally, Jung et al. (2011) reported that 800µg/day for 3 years of folic 
acid did not influence DNA methylation in moderately hyperhomocysteinemic Dutch males 
and females aged 50-70 years (56). 
In contrast, results from Pufulete et al. (2005) suggest DNA hypomethylation brought about by 
a low dietary intake of folate could be reversed by folate supplementation. It was reported that 
a 400µg/day for 10 weeks supplement of folic acid, in patients with colorectal adenoma, 
increased serum folate from 7.4 to 13.4µg/l, and plasma homocysteine decreased 12%, while 
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DNA methylation increased by 31 and 25% in leucocytes and colonic mucosa respectively 
(57). Interestingly, Park et al. (2017) found folate supplementation produced distinct 
differences in DNA methylation patterns dependent on body weight. In this study, 
supplementation of 800µg/day for 8 weeks in normal weight and obese females aged 18-35 
increased serum folate by 86.2 and 109.6% respectively. Before supplementation, 10.7% of 
CpG sites differed between the different weight categories; this rose to 15.2% after 
supplementation. Higher levels of methylation were observed in 52.9% and 55.0% of obese 
women before and after treatment respectively. After treatment, CpG sites were more likely to 
have reduced levels of methylation; 67.9 and 75.8% for normal weight and obese females 
respectively. Interestingly, while the supplementation induced methylation changes in genes 
associated with neural tube closures in women of normal weight, overweight women exhibited 
changes in methylation in genes associated with folate metabolism, methylation and vitamin B 
metabolism (58). 
Conversely, a 3 month 100µg/day, 400µg/day, and a 4000µg/day supplement of folate resulted 
in an 11.5, 11.7 and 18.9% reduction in % 5 methyl-deoxycytidine respectively in coagulated 
blood samples from Chinese women of reproductive age, who showed an average % methyl-
deoxycytidine level of 4.42±0.12% at enrolment. Interestingly, it was observed that genotype 
can influence the DNA methylation response to dietary folate. When analysing the effect of a 
3 month 4000µg/day folate supplement in the presence of the MTHFR 677C→T variant, it was 
found that there was an 11.6, 18.8 and 19.5% reduction in % 5 methyl-deoxycytidine for the 
CC, CT and TT genotypes respectively compared to baseline results (59).  
 
5.3. Caloric Restriction 
Recent evidence has suggested that caloric restriction (CR), even in the short term, could 
potentially ameliorate aberrant methylation in disease associated genes as observed in age 
related methylation drift (60). Maegawa et al. (2017) detailed that CR was able to counteract 
hypermethylation associated with ageing without producing novel methylation patterns. In 
both DNA from whole blood of mice and Rhesus monkeys, a significant inverse relationship 
was observed between CR and the rate of methylation drift. Specifically, there was an average 
DNA methylation, across 24 genes, of 26±2% and 27±0.7% for aged mice and Rhesus monkeys 
fed ad libitum, compared to 17±0.7 and 24±0.9% in aged mice and Rhesus monkeys 
respectively who underwent CR (12). Hahn et al. (2017) showed that a 40% dietary restriction 
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in mice resulted in a reduced number of differentially methylated regions in DNA extracted 
from the liver. In aged mice fed ad libitum, age differentially methylated 3176 regions, of which 
1945 became hypermethylated and 1231 became hypomethylated, whereas aged mice who 
underwent 40% DR exhibited only 2250 differentially methylated regions were identified, of 
which 1512 became hypermethylated and 738 became hypomethylated (61). To further this, 
Wang et al. (2017) reported that 40% CR resulted in a predicted 9.4 month reduction in 
epigenetic age within the livers of 22 month old mice compared with age-matched controls 
(62), therefore it appears that CR may provide a promising treatment strategy for aberrant DNA 
methylation.  
 
5.4. Drug Therapy  
Due to the association of hypermethylation of promoters and tumour suppressor gene silencing 
in cancer, the use of drugs which ameliorate this change may provide a successful method for 
reducing DNA methylation in these regions and enable the re-expression of these genes. 
Hypomethylating agents 5-azacytidine (azacytidine) or 5-Aza-2'-deoxycytidine (decitabine) 
are 2 such examples, which were approved for use by the European Medicines Agency (EMA) 
in 2008 and 2012 respectively for patients with myelodysplastic syndromes (MDS). 
Following the cellular uptake of decitabine, it is phosphorylated to 5-aza-2’-deoxycytidine-
triphosphate, and becomes incorporated into DNA strands in place of cytosines within CpG 
sites. The substitute nucleotide binds DNA methyltransferases similarly to cytosine, however 
due to the substitution of carbon-5 in the cytosine ring for nitrogen, β-elimination is inhibited 
and thus covalent bonding is irreversible. This results in enzyme inhibition and eventual 
degradation of the bound enzyme, and thus a reduction in DNA methylation. Azacytidine acts 
in a similar way, however it acts upon RNA. Interestingly, during phosphorylation, 
approximately 10-20% is converted to a 5-aza-2’-deoxycytidine-triphosphate precursor and 
thus acts upon DNA (63).  
While meta-analysis data suggest that both Azacitadine and Decitabine are superior to best 
supportive care in patients with MDS (64), there is conflicting evidence on the superiority of 
these drugs. For instance, Lee et al. (2013) conducted a comparative analysis of Azacytidine, 
given for 7 days in a 28 day cycle, and Decitabine, given for 5 consecutive days in a 28 day 
cycle, in patients with myelodysplastic syndromes, and response rates of 46 and 52%, a median 
peak response at 4.2 and 4.0 months, and median survival time of 23.3 and 22.9 months were 
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reported respectively. While these parameters were not statistically different from one another, 
it was established that the survival rate was significantly improved in patients >65 taking 
Azacitidine, and patients showed reduced vulnerability to infection, in addition to a lower 
incidence of grade 3/4 of cytopenia (65). Xie, Jiang and Xie (2015) conducted a meta-analysis 
of 11 trials, containing 1392 MDS patients and similarly found that while there was no 
significant difference between the rate of complete response in patients undertaking Decitabine 
or Azacytidine treatment (13 vs. 12%), Azacitidine treatment resulted in a significantly higher 
overall response rate compared with Decitibine (73 vs. 42%). Moreover, a statistically 
significant improvement in overall survival was observed for Azacytidine treatment when 
compared to best supportive care, while no statistical difference was observed for Decitabine 
treatment (66).  
In contrast, results from a randomised phase II trial in patients with low/intermediate-risk MDS 
or chronic myelomonocytic leukemia indicated an overall response rate of 70 and 49% for 
patients who received intravenous Decitabine or Azacytidine for 3 consecutive days, on a 28 
day cycle, respectively. Furthermore, the one year event-free survival rate was significantly 
greater in patients who received Decitabine (74 vs. 55%). In addition, haematological 
improvements were observed in 24% of patients treated with Decitabine compared with 8% of 
Azacytidine patients, and of the patients who were transfusion dependent at the start of the 
trail, 32 and 16% became transfusion independent following Decitabine or Azacytidine 
treatment (67).  
However, it is important to note the use of such hypomethylating agents should be used with 
caution due to selectivity concerns. For instance, in one study which used Azacytidine to treat 
the non-invasive breast cancer cell lines MCF-7 and ZR-75-1, the drug lowered DNMT1 and 
DNMT3b and methylation within the promoters of several pro-metastatic genes, including uPA 
and MMP2, leading to gene expression. Furthermore, it was shown that treatment increased 
the invasiveness of both cell lines (68). 
 
6. Detecting DNA Methylation 
In recent years a systems orientated approach has become common place in bioscience research 
(69-73). The essence of this approach is to utilise novel approaches to study molecules, cells, 
or entire organisms. Nutrition research is no different and is beginning to benefit from this new 
paradigm (74-80). It can be argued electrochemical techniques come under this umbrella of 
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systems techniques. For instance, recently, there has been heightened interest in using 
electrochemical techniques to detect DNA methylation as it can be a rapid, easy to use and cost 
effective solution to many of the challenges posed by more conventional methods and enables 
the quantitative analysis of complex biochemical systems (81). 
There are several techniques that can be employed to analyse DNA methylation, many of which 
require prior bisulphite conversion, which converts unmethylated cytosines to uracil, while 
methylated cytosines remain unchanged. These techniques include bisulphite sequencing (82), 
methylation specific PCR (83), pyrosequencing (84) and immuno-based recognition (85). 
Methods which don’t require prior bisulphite conversion include high performance liquid 
chromatography (86), mass spectrometry (87), microarray analysis (88), surface plasmon 
resonance (89) and surface enhanced Raman spectroscopy (90). Many of these methods have 
several draw backs including the need for expensive laboratory equipment and/or biological 
molecules coupled with long analysis times and the requirement for highly skilled operators.  
An example of an elegant electrochemical DNA-methylation sensor, is the eMethylsorb 
method of Koo et al. (2014).  The method consists of two steps.  First, a gold electrode is 
exposed to a solution of bisulfite modified DNA.  This exploits the findings of Kimura-Suda 
et al. (2003), who demonstrated that single stranded homo-oligonucleotides adsorbed onto gold 
with the following affinity A > C ≥ G > T (91). The DNA adsorption essentially blocks (or 
passivates) the gold surface, decreasing its reactivity.  The lower the methylation level of the 
original DNA, the higher the number of adenines present in the bisulfite treated sample. 
Consequently, unmethylated DNA results in a more passivated and less reactive surface than 
methylated DNA.  In the second step of the emethylsorb method, the reactivity of the gold 
electrode surface is measured in an electrochemical reaction.  Initially, Koo et al. developed 
the eMethylsorb method using disposable gold screen printed electrodes (consisting of a 4mm 
diameter gold working electrode, gold counter electrode and silver reference electrode) 
exposed to solutions of synthetic oligonucleotides diluted in 5X SSC buffer, designed to 
represent bisulphite modified and asymmetrically amplified methylated and unmethylated 
versions of a 53 base section, containing 8 CpG sites, of the EN1 gene promoter.  After the 
adsorption step, the reactivity of the modified gold service was measured by performing 
differential pulse voltammetry (DPV) in an electrolyte containing 2.5 mM ferrocyanide, 2.5 
mM ferricyanide and 100mM KCl, where the peak current for the reduction of Fe3+ to Fe2+ 
inversely correlated with the level of DNA adsorption on the gold electrode.  
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Optimisation of the adsorption step revealed the greatest current response difference (between 
methylated and unmethylated samples) was observed when 50nM of synthetic oligonucleotides 
was adsorbed for 10 minutes (in quiescent solution) at pH 7.0. The method was used to 
successfully detect 10% methylation in heterogeneous samples of synthetic oligonucleotides. 
Furthermore, the technique was able to detect 10% methylation in heterogeneous samples 
containing various combinations of MCF-7 and whole genome amplified (WGA) DNA. 
Interestingly, the sensitivity of the method was significantly greater for these 140 base DNA 
samples in comparison to the 53 base synthetic oligonucleotides (92). 
In a related study, the same research group, used a 2 mm gold disk working electrode (Pt 
counter electrode and Ag/AgCl reference electrode) to detect methlaytion levels in the same 
synthetic oligonucleotides (in 5X SSC buffer).  The electrochemical reactivity of the modified 
gold surface was measured via DPV in a solution of 2.5 mM ferrocyanide, 2.5 mM ferricyanide 
and 10 mM PBS. Using the two-step eMethylsorb procedure, the greatest relative current 
difference was observed between methylated and unmethylated DNA, when 200nM DNA was 
adsorbed for 10 minutes (in quiescent solution) at pH 7.0. Again a negative linear relationship 
between % methylation in heterogeneous samples of synthetic methylated and unmethylated 
oligonucleotides and relative current response was observed (R2 = 0.99398). Sina et al. (2014) 
also investigated the effect of the number of methylated CpG sites within the 53 base synthetic 
oligonucleotide (0, 1, 4, and 8). A negative linear relationship was observed between the 
number of methylated CpG sites and relative DPV current response (R2 = 0.971411). Finally it 
was determined that only 20µl of secondary PCR product (from real DNA samples) in 200µl 
buffer was required to produce a considerable difference in relative current. Once again, the 
sensitivity of the method greatly improved on moving from synthetic to real DNA samples 
(89). 
Our project set out to improve the repeatability and sensitivity of the eMethylsorb method via 
a new approach to the adsorption step and the electrochemical technique.  The new procedure 
was optimised using 30 base synthetic oligonucleotides, containing 6 CpG sites, designed to 
represent bisulphite modified and asymmetrically amplified methylated and unmethylated 
versions of a region downstream of the transcription site of the EN1 gene promoter (93).   
It was also imperative to test if % methylation could be determined using these optimised 
electrochemical procedures in a heterogeneous sample. This was to reflect biopsy samples 
gained in a clinical setting, as tumours are often found to contain cells exhibiting diverse 
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phenotypic features; including methylation status. This phenomenon, termed intra tumour 
heterogeneity, has been observed in multiple cancers including breast (94), lung (95), 
endometrial (96) and prostate cancer (97). To test the applicability of the procedure in detecting 
methylation in DNA derived from humans, the procedure was repeated using bisulphite 
modified and asymmetrically amplified 140 base ssDNA from the EN1 region of DNA 
extracted from the breast cancer cell line MCF-7 (methylated), and WGA DNA 
(unmethylated). Our method successfully detected high methylation levels in the breast cancer 
cells (93).  
 
7. Conclusion 
This review has highlighted a wide variety of dietary components which can influence DNA 
methylation status during life. Based on our survey of the literature it can be argued many 
instances of aberrant DNA methylation are the direct result of diet. Nowhere is this more 
apparent than cancer, because the methylation changes which are a hallmark of many cancers 
are influenced by dietary factors such as folate consumption, calorie intake, and polyphenol 
content. This review has reinforced the idea that identifying DNA methylation changes early 
could be an effective means of predicting cancer risk. An important take home message from 
our review is that the early detection of cancer could be achieved by monitoring methylation 
levels within biomarker genes such as the EN1 gene.  Finally, this review has revealed that the 
goal of early cancer detection could be achieved by using novel electrochemical techniques to 
quantify DNA methylation levels. There is little doubt that techniques such as this will prove 
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Figure 1 Overview of DNA Methylation. 
De novo methylation is regulated by DNMT3a and DNMT3b and uses SAM as a methyl donor. 
The new methylation pattern is passed on to daughter cells through DNMT1, which acts on 
hemi-methylated DNA. DNA can become demethylated through the TET and TDG enzymes 
and BER. DNMT, DNA methyltransferase; TET, ten-eleven translocation enzymes; BER base 
excision repair, 5mC, 5-methylcytosine; 5hmC, 5-hydroxymethlcytosine; 5fC, 5-
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